NT-0796 is an oral, brain-penetrant NLRP3 inhibitor that selectively regulates chronic inflammation, a key driver of cardiometabolic diseases ...
Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.
On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback